Clinical trial
Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen
NCT01076751 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen
- Lead sponsor
- Sanofi
- Phase
- Observational
- Overall status
- Terminated
- Start date
- February 28, 2010
- Completion date
- October 31, 2010
- Enrollment
- 82 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.